EHEmily Hunt

Emily Hunt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily Hunt has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Review of Prognostic Significance of Quantitative BPE Measurements

    by Jeremy Weiss, Emily Hunt, Yihui Zhu, Tim Q. Duong, Takouhie Maldjian

    Background/Objectives: Background parenchymal enhancement (BPE) on breast magnetic resonance imaging reflects hormonal and vascular activity of fibroglandular tissue and is studied as a prognostic marker for breast cancer. This paper serves as a review that evaluates quantitative methods for BPE measurements for predicting treatment outcomes. Methods: PubMed was searched for papers on evaluating BPE with outcomes to compare, such as pathologic complete response, recurrence-free survival, disease-free survival, and overall survival, from 2015 to 2025. In total, eleven papers using quantitative methods to measure BPE were selected. Results: Quantitative results showed that BPE reduction during neoadjuvant chemotherapy and high pre-treatment/baseline BPE are linked to improved treatment response and reduced risk of recurrence. Conclusions: Quantitative assessment methods yield objective and reproducible prognostic information. Incorporating quantitative BPE measurements alongside tumor-focused imaging features may further improve predictive accuracy in clinical settings.


  • Open Access

    Analysis of Neutrophil/Lymphocyte Ratio as a Potential Biomarker Stratified by Breast Cancer Histologic Subtype

    by Emily Hunt, Matthew Davis, Wei Hou, Henrietta Bains, Timothy Darby, Julia Hou, Julie Chung, Roham Hadidchi, Tim Q. Duong, Takouhie Maldjian

    Background/Objectives: Breast cancer is the most common cancer in women. The neutrophil/lymphocyte ratio (NLR) is an emerging biomarker from peripheral blood that has been associated with breast cancer prognosis in some studies; however, some studies fail to demonstrate an association. We stratified breast cancer patients into invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) cohorts to evaluate if any meaningful association could be found in either cohort between NLR and mortality. Additionally, no prior studies have examined the relationship between NLR and background parenchymal enhancement (BPE) on breast MRI, an imaging feature linked to increased breast cancer risk and a potential imaging prognostic biomarker, so we examined the relationship between BPE and NLR in the two cohorts. Methods: This retrospective study included 794 breast cancer patients who had either IDC or ILC. Radiologists’ MRI reports and their BI-RADS categorization of BPE (1 = minimal, 2 = mild, 3 = moderate, 4 = marked) were extracted and recorded. The NLR was calculated from blood counts obtained prior to treatment. Tumor characteristics were also recorded. Results: For patients with ILC, NLR was found to be associated with mortality. Additionally, patients with ILC and a high BPE had a significantly higher mean NLR compared to all other groups, including low BPE groups and all IDC groups. Conclusions: There is potential value in using NLR, a readily available blood biomarker, in models predicting prognosis in ILC patients.


  • Open Access

    Male Breast Cancer in a Bronx Urban Population: A Single-Institution Retrospective Observational Study

    by Kristen Lee, Bhakti Patel, Ruth Samson, Emily Hunt, Christian L. Sellers, Takouhie Maldjian

    Background/Objectives: This study seeks to evaluate the clinical characteristics of newly diagnosed male breast cancers within the traditionally underserved Bronx population at risk for poorer health outcomes. Methods: We retrospectively searched our database for male patients who presented for mammographic evaluation between 1 January 2016 and 1 October 2024. The primary outcomes were the prevalence of biopsy-proven male breast cancer and its association with gynecomastia and TNM stage at diagnosis. Clinical data, including TNM staging, receptor status, risk factors, and patient demographics, were recorded for patients with biopsy-proven breast cancer based on biopsy results. Two dedicated breast imagers retrospectively evaluated mammograms of these patients to determine by consensus the presence of gynecomastia. Analyses were descriptive in nature. Results: During the study period, 423 screening mammograms and 1775 diagnostic mammograms were performed on male patients. Twenty-six male patients with biopsy-proven breast cancer were identified (two were bilateral and four were multifocal). In total, 69% of our male breast cancer patients (18 out of 26) demonstrated gynecomastia, which was similar across demographic groups, ranging from 63 to 75%. Out of the three patients with Stage 4 disease, two were Black and one was White. Stage 3 or higher disease was seen in 29% of our Black patients, 12% of our White patients, and 0% of our Hispanic patients. Conclusions: Male breast cancer in this Bronx population was frequently associated with gynecomastia and showed notable demographic disparities. Black patients presented with more advanced disease than other demographic groups. These descriptive findings highlight areas of further investigation and may help inform future outreach and early detection efforts in high-risk, underserved communities. This retrospective, single-institution analysis was limited by a small sample size and did not include formal statistical testing; therefore, the findings are descriptive and warrant validation with larger cohorts.

  • Reply to Editorial Comment on “Physician and Patient Adherence to Kidney Stone Prevention Guidelines in a Diverse, Low-Resource, Urban Population”

    by Emily R. Hunt, Tyler Bergeron, Beth Edelblute, Kara L. Watts, Alexander C. Small, Dima Raskolnikov

  • Physician and Patient Adherence to Kidney Stone Prevention Guidelines in a Diverse, Low-resource, Urban Population

    by Emily R. Hunt, Tyler Bergeron, Beth Edelblute, Kara L Watts, Alexander C. Small, Dima Raskolnikov


  • Open Access

    Respiratory-Responsive Vocal Biomarker for Asthma Exacerbation Monitoring: Prospective Cohort Study (Preprint)

    by Erik Larsen, Xinyu Song, Dale Joachim, Peter Ch'EN, Samuel Green, Emily Hunt, Savneet Kaur, Robin Nag, Olivia Pisani, Sherron Thomas, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Asthma exacerbations are a significant issue due to poor perception and failure of traditional monitoring techniques to capture real-time changes in respiratory function. There is a need for strategies to enhance recognition and facilitate timely intervention. Objective: To evaluate the efficacy of a respiratory-responsive vocal biomarker (RRVB), accessible via smartphone application, as a convenient real-time tool for monitoring asthma exacerbations and respiratory states. Methods: In this three-month prospective cohort study, 84 asthma patients recorded daily 6-second vocal samples, generating RRVB scores. The RRVB's ability to predict asthma exacerbations and respiratory states (normal function, mild events, exacerbations) was assessed using risk ratios (RR) and confidence intervals (CIs). Respiratory states were defined using peak expiratory flow (PEF) and self-reported wellbeing, with exacerbations identified by a decline in both PEF and wellbeing, and mild events by a decline in one measure. Results: RRVB scores significantly predicted asthma exacerbations, with a risk ratio of 2.15 (95% CI: 1.62-2.85, p < .001), and 3.57 (95% CI: 2.70-4.73, p < .001) using normalized scores adjusted for individual characteristics. However, time-averaged RRVB scores did not significantly correlate with asthma control as measured by the Asthma Control Test (ACT), with a risk ratio of 1.17 (95% CI: 0.96-1.44, p = .12). A total of 58% of participants remained engaged throughout the study, reporting high satisfaction with the tool's usability and perceived benefits for asthma management. Conclusions: This study demonstrates potential enhancements in asthma management through more accessible and continuous monitoring of respiratory function offered by the RRVB tool, which was shown to provide an effective, real-time, and user-friendly approach for detecting potential exacerbations. Clinical Trial: clinicaltrials.gov: NCT05850390


  • Open Access

    Respiratory-Responsive Vocal Biomarker for Asthma Exacerbation Monitoring: Prospective Cohort Study (Preprint)

    by Erik Larsen, Xinyu Song, Dale Joachim, Peter Y Ch'EN, Samuel M Green, Emily Hunt, Savneet Kaur, Robin Nag, Olivia Pisani, Sherron Thomas, et al.

    BACKGROUND Asthma exacerbations remain a major challenge in asthma management, often due to delayed recognition and limitations of conventional monitoring tools such as peak flow meters and symptom questionnaires. These tools are typically effort dependent or retrospective, making them less suited for continuous, real-time monitoring. A novel, smartphone-based respiratory-responsive vocal biomarker (RRVB) may offer an accessible and noninvasive approach for dynamic assessment of respiratory health. This RRVB has previously demonstrated generalizable performance in cross-sectional cohorts across multiple respiratory conditions, including asthma, chronic obstructive pulmonary disease, and COVID-19, in populations spanning India and the United States. This study extended this work by evaluating the real-world, longitudinal performance of the same RRVB tool for daily asthma exacerbation monitoring via smartphones in home settings. OBJECTIVE This study aimed to evaluate the efficacy of the RRVB as a convenient real-time tool for monitoring asthma exacerbations and respiratory states in a real-world, longitudinal setting. METHODS In this prospective cohort study, 84 adult patients with asthma were enrolled from an academic medical center and followed for 90 days. Participants submitted daily 6-second voice samples and conducted peak expiratory flow measurements and surveys, including symptom reports and asthma control assessments. RRVB scores were generated in real time on the app. Asthma states (normal function, mild event, and exacerbation) were defined based on both peak expiratory flow and self-reported well-being. Risk ratios were calculated to assess the predictive validity of RRVB scores for identifying exacerbation events. Engagement was measured via frequency of completed sessions, and participant experience was evaluated through exit surveys. RESULTS RRVB scores significantly stratified asthma states. The risk of experiencing an exacerbation was 2.15 times higher (95% CI 1.62-2.85; P<.001) with elevated RRVB scores and 3.57 times higher (95% CI 2.70-4.73; P<.001) using normalized scores adjusted for individual characteristics. RRVB scores did not significantly correlate with the Asthma Control Test (risk ratio=1.17, 95% CI 0.96-1.44; P=.12), highlighting its role as a momentary signal rather than a proxy for longitudinal control. Engagement was moderate or higher (≥26 total app sessions) in 58% (49/84) of participants. Among survey respondents, 93% (43/46) found the app easy to use, 89% (41/46) reported a positive overall experience, and 87% (40/46) indicated that they would use a similar tool in the future. Fewer participants (32/46, 70%) reported understanding the RRVB scores, suggesting a need for improved score interpretability and user guidance in future implementations. CONCLUSIONS The RRVB tool demonstrated effective real-time detection of asthma exacerbations and dynamic respiratory states, supporting its potential as a noninvasive, user-friendly, and physiologically grounded digital biomarker for asthma monitoring. These findings provide foundational evidence for broader deployment and integration of voice-based tools to support proactive, real-world asthma management.

  • Enhancing asthma research and improving health equity through decentralized clinical trials (DCTs) and mHealth technology

    by Emily R. Hunt, Sara L. Hantgan, Sunit P. Jariwala

    The COVID-19 pandemic led to widespread disruption and termination of clinical research and a prompt adoption of mobile health (mHealth) technologies in the healthcare space. As the United States' healthcare system has rapidly become reliant on remotely conducted activities, the implementation of decentralized methods using mHealth technology in research investigation has become a necessary alternative to traditional in-person cohort studies. The aim of this article is to: report successful and unsuccessful examples of remote asthma clinical studies, explore the benefits and potential drawbacks of virtual clinical investigation, discuss the potential impact on equity and representation in asthma research, and provide suggestions through which investigators can implement decentralized clinical trials. Enhanced study accessibility, participant diversity, safety measures, and research efficacy are some of the benefits identified with a focused discussion on the impact on equity that decentralized clinical trials renders. Furthermore, potential concerns regarding regulatory compliance, data privacy, and effective mHealth design and solutions are discussed. Despite the setbacks and interruptions faced by the study participants and investigators due to the pandemic, the transition to decentralized clinical studies using mHealth technology is a positive, feasible step toward innovation and equity in the allergy and immunology field.